<!-- --><!-- --><style type="text/css">@import url(https://www.blogger.com/static/v1/v-css/navbar/3334278262-classic.css); div.b-mobile {display:none;} </style> </head><body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar.g?targetBlogID\07511139315\46blogName\75NanoNovus\46publishMode\75PUBLISH_MODE_BLOGSPOT\46navbarType\75BLUE\46layoutType\75CLASSIC\46searchRoot\75http://nanonovusblog.blogspot.com/search\46blogLocale\75en_US\46v\0752\46homepageUrl\75http://nanonovusblog.blogspot.com/\46vt\75-6835450727142964005', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe" }); } }); </script>

Monday, May 23, 2005

Still Bullish on pSivida

Today, I had a short article in The Motley Fool about pSivida's recent turn-a-round.

It has been painful to watch pSivida's slide since it was listed on Nasdaq in Februrary but as I said in an earlier posting, I thought the price decline would be temporary because, in part, it wasn't being driven by any particular news. This is not the case with its reversal -- which is being driven by positive news. (I list the three recent positive developments which are contributing to the rebound in the Motley Fool article.)

As I have said all along, the thing that will really move this stock forward will be news that one of "the top 5 global pharma companies" has decided to move forward with product development using pSivida's BilSilicon technology. Such a development would serve as big validation of its technology. Moreover, if this occurs, the Big Pharma company will not only pay for product development and testing, it is likely to pay pSivida some healthy milestone payments.

I remain bullish on pSivida and encourage investors to stay patient. (Full Disclosure: I own pSivida stock).

Related Links:
pSivida: Down Under Company has Big Upside Potential
Starpharma "Nano" star on the rise?
Elan Good News for Nanotech Investors?